JP2007515469A5 - - Google Patents

Download PDF

Info

Publication number
JP2007515469A5
JP2007515469A5 JP2006546357A JP2006546357A JP2007515469A5 JP 2007515469 A5 JP2007515469 A5 JP 2007515469A5 JP 2006546357 A JP2006546357 A JP 2006546357A JP 2006546357 A JP2006546357 A JP 2006546357A JP 2007515469 A5 JP2007515469 A5 JP 2007515469A5
Authority
JP
Japan
Prior art keywords
antibody
use according
patient
group
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006546357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/004103 external-priority patent/WO2005063289A1/en
Publication of JP2007515469A publication Critical patent/JP2007515469A/ja
Publication of JP2007515469A5 publication Critical patent/JP2007515469A5/ja
Pending legal-status Critical Current

Links

JP2006546357A 2003-12-22 2004-12-09 Ｃｄ４０抗体製剤および方法 Pending JP2007515469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53163903P 2003-12-22 2003-12-22
PCT/IB2004/004103 WO2005063289A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011100868A Division JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法

Publications (2)

Publication Number Publication Date
JP2007515469A JP2007515469A (ja) 2007-06-14
JP2007515469A5 true JP2007515469A5 (https=) 2008-01-31

Family

ID=34738672

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006546357A Pending JP2007515469A (ja) 2003-12-22 2004-12-09 Ｃｄ４０抗体製剤および方法
JP2011100868A Expired - Fee Related JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法
JP2014121342A Pending JP2014205692A (ja) 2003-12-22 2014-06-12 Ｃｄ４０抗体製剤および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011100868A Expired - Fee Related JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法
JP2014121342A Pending JP2014205692A (ja) 2003-12-22 2014-06-12 Ｃｄ４０抗体製剤および方法

Country Status (20)

Country Link
US (4) US20050136055A1 (https=)
EP (3) EP1706143A1 (https=)
JP (3) JP2007515469A (https=)
KR (2) KR20080023766A (https=)
CN (2) CN102552905A (https=)
AU (1) AU2004308749B2 (https=)
BR (1) BRPI0418029B8 (https=)
CA (2) CA2549652C (https=)
DK (1) DK2218461T3 (https=)
ES (1) ES2580002T3 (https=)
HU (1) HUE027717T2 (https=)
IL (2) IL175540A (https=)
NO (1) NO343797B1 (https=)
NZ (2) NZ583179A (https=)
PL (1) PL2218461T3 (https=)
RU (1) RU2355421C2 (https=)
SI (1) SI2218461T1 (https=)
TW (1) TWI359671B (https=)
WO (1) WO2005063289A1 (https=)
ZA (1) ZA200603804B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090304687A1 (en) * 2005-12-09 2009-12-10 Seattle Genetics , Inc. Methods of using cd40 binding agents
MX2008013993A (es) * 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2735421A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
PT3444271T (pt) 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
BR112017008959A2 (pt) 2014-10-29 2018-01-16 Seattle Genetics, Inc. método para tratamento de uma doença.
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
CA3042867A1 (en) 2016-11-04 2018-05-11 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CN111344304B (zh) 2017-06-01 2023-09-01 Pb免疫治疗公司 新型抗cd40抗体及其用途
EP3418302A1 (en) * 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
EP3630827A1 (en) * 2017-06-02 2020-04-08 H. Hoffnabb-La Roche Ag Administration routes for immune agonists
AU2019255781A1 (en) 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
JP7626698B2 (ja) * 2018-09-28 2025-02-04 リビジェン バイオファーマ ホールディングス リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
CN112996818B (zh) * 2018-09-28 2022-06-21 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
US20240254248A1 (en) * 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
CN113271964A (zh) 2019-01-11 2021-08-17 诺华股份有限公司 化脓性汗腺炎治疗中使用的抗cd40抗体
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
US20230227567A1 (en) * 2020-06-04 2023-07-20 Selvax Pty Ltd Agonist anti-cd40 antibodies
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
JPH03204821A (ja) * 1989-12-28 1991-09-06 Green Cross Corp:The モノクローナル抗体含有水溶液の加熱処理方法
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
NZ273504A (en) * 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
ES2222463T3 (es) * 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2635352C (en) * 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
EP1181054A1 (en) * 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
WO2001047554A1 (fr) * 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
US6358670B1 (en) * 1999-12-28 2002-03-19 Electron Vision Corporation Enhancement of photoresist plasma etch resistance via electron beam surface cure
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1322383B9 (en) * 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7771951B2 (en) * 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080009439A1 (en) * 2002-11-05 2008-01-10 Alsobrook John P Compositions and Methods of Use for a Fibroblast Growth Factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Similar Documents

Publication Publication Date Title
JP2007515469A5 (https=)
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2012067116A5 (https=)
JP2022531939A5 (https=)
CN109562281B (zh) 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
KR20240056564A (ko) T 세포 림프종을 치료하기 위한 약물을 제조하는 데 있어서 ezh2 억제제의 용도
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2005515966A5 (https=)
JP2008507536A5 (https=)
WO2010081817A1 (en) Method for treating colorectal cancer
JP2006513184A5 (https=)
CN106535895A (zh) 丁型肝炎病毒感染的治疗
JP2005506345A5 (https=)
CN108367001A (zh) 治疗丁型肝炎病毒感染
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2024016209A5 (https=)
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
IL307751B1 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
JP2006514681A5 (https=)
JP2004525143A5 (https=)
JP2007504268A5 (https=)
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
JP2005508323A5 (https=)
CN120826242A (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
WO2024120523A1 (zh) 一种治疗前列腺癌的药物组合及其应用